Half-year report · Q2
4574.TEDINET S100WI6C
Period2025-01-01 → 2025-06-30
Filed2025-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥6.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥482m | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥688m | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥528m | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥724m | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥898m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥12.9bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥13.4bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.7bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥4.9bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥8.1bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.2bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥362m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥256m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥135m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥562m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.9 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.24 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
| Otherother segments | revenue | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | segment profit | 2024-01-01 → 2024-06-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥401m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥195m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-06-30 | ¥884m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 523
| Item | Context | Value | Unit |
|---|---|---|---|
| Subtotal ope cf | Prior1YTDDuration | 53000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 55000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 13000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 8000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -4000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -3000000 | JPY |
| Proceeds from compensation ope cf | Prior1YTDDuration | 200000000 | JPY |
| Proceeds from compensation ope cf | CurrentYTDDuration | 14000000 | JPY |
| Proceeds from subsidy income2 ope cf | Prior1YTDDuration | － | JPY |
| Proceeds from subsidy income2 ope cf | CurrentYTDDuration | 3000000 | JPY |
| Proceeds from insurance income ope cf | Prior1YTDDuration | 1000000 | JPY |
| Proceeds from insurance income ope cf | CurrentYTDDuration | 1000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -7000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -17000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 256000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 61000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -1000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | － | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 30000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | － | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -72000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -148000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 0 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | － | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -24000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -2000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 447000000 | JPY |
| Payments for asset retirement obligations inv cf | Prior1YTDDuration | -68000000 | JPY |
| Payments for asset retirement obligations inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -135000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | 295000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -603000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -673000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -14000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -11000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -1000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | － | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | 59000000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | － | JPY |
| Other net fin cf | Prior1YTDDuration | -2000000 | JPY |
| Other net fin cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -562000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -684000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 113000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -65000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -327000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -392000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 5244000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 4532000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |